Lifeward Posts 16% Revenue Growth in Q2 2026 on Strong Commercial Execution
Event summary
- Lifeward reported a 16% year-over-year revenue increase to $6.6 million in Q2 2026, driven by stronger sales of ReWalk exoskeletons and AlterG products.
- The company raised $5.6 million in growth capital through a strategic financing closed on July 6, 2026, with an additional $5.6 million available upon achieving specific milestones.
- Lifeward launched a pilot program with Ottobock Care to broaden access to the ReWalk Personal Exoskeleton across the U.S.
- The company's gross margin decreased to 41% from 44% year-over-year due to higher tariffs, foreign exchange fluctuations, and revenue-sharing expenses related to the Oramed transaction.
- Key executive changes include the departure of CFO Almog Adar effective September 30, 2026, and the resignation of three board members.
The big picture
Lifeward's Q2 2026 results highlight its progress in transforming into a scaled restorative healthcare company, leveraging capital-efficient distribution strategies and expanding its rehabilitation platform. The governance changes and executive transition signal a potential shift in strategic direction as the company navigates its evolution beyond neurorehabilitation into high-value therapeutic platforms.
What we're watching
- Commercial Momentum
- Whether Lifeward can sustain its revenue growth trajectory in the second half of 2026, particularly with the expansion of its ReWalk exoskeleton through partnerships like Ottobock Care.
- Financial Flexibility
- The pace at which Lifeward will access the additional $5.6 million in growth capital tied to achieving a 150% increase in ReWalk sales or stock performance milestones.
- Leadership Transition
- How the departure of CFO Almog Adar and the resignation of three board members will impact strategic decision-making and operational continuity.